The U.S. Embassy in Libreville announces a new donation by the U.S. Government of 101,790 doses of Pfizer’s Covid-19 vaccine as part of the U.S. Administration’s global efforts to fight the COVID-19 pandemic. The United States has already donated more than 280 million doses from its domestic supply to more than 100 countries, over 400,000 of which went to Gabon.
“We are sharing these doses safely, equitably and without conditions. We do so with the sole purpose of protecting and saving lives,” said Mr. Samuel Watson, Chargé d’Affaires, a.i. at the U.S. Embassy in Libreville.
Through the partnership with COVAX, and the African Union, the United States delivered 100,620 doses of the Pfizer COVID-19 vaccine to our friends in Gabon on September 23. A second delivery of 101,790 doses of Pfizer vaccine was made on October 28.
Safe and effective vaccines are our best tool for ending the pandemic, and the United States has committed to purchasing and distributing 1.1 billion doses of COVID-19 vaccine worldwide. In addition to the Pfizer vaccine, the United States has also delivered 168,000 doses of Johnson&Johnson vaccine to Gabon. Both the Pfizer and J&J vaccines are approved by the U.S. Food and Drug Administration and Centers for Disease Control, as well as by the World Health Organization.
The United States looks forward to continuing to work with the Government of Gabon, the private sector, and civil society to stop the spread of the virus in Gabon and to encourage vaccination.Distributed by APO Group on behalf of U.S. Embassy in Gabon.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.